“Did You Climax or Are You Just Laughing at Me?” Rare Phenomena Associated With Orgasm

Reinert, Anna; Simon, James A.

doi:10.1016/j.sxmr.2017.03.004

Cited by 10 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women and men with narcolepsy have reported forms of sexual dysfunction, including cataplexy with orgasm (termed orgasmolepsy) and erectile dysfunction with narcolepsy treatment, suggesting that individuals with narcolepsy may experience distinct challenges associated with sexual intimacy. 106 , 109 Orgasmolepsy episodes have been described as involving complete loss of muscle tone, but not lasting more than 30 seconds. Case studies indicate that cataplexy treatments may be effective in reducing orgasmolepsy for some patients, but rigorous studies in this area have not been pursued.…”

Section: Challenges and Prospects For Specific Populations With Narcomentioning

confidence: 99%

<p>Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns</p>

Barker¹,

Flygare²,

Paruthi³

et al. 2020

NSS

View full text Add to dashboard Cite

Narcolepsy is a neurological disorder of the sleep-wake cycle characterized by excessive daytime sleepiness (EDS), cataplexy, nighttime sleep disturbances, and REM-sleep-related phenomena (sleep paralysis, hallucinations) that intrude into wakefulness. Dysfunction of the hypocretin/orexin system has been implicated as the underlying cause of narcolepsy with cataplexy. In most people with narcolepsy, symptom onset occurs between the ages of 10 and 35 years, but because the disorder is underrecognized and testing is complex, delays in diagnosis and treatment are common. Narcolepsy is treated with a combination of lifestyle modifications and medications that promote wakefulness and suppress cataplexy. Treatments are often effective in improving daytime functioning for individuals with narcolepsy, but side effects and/or lack of efficacy can result in suboptimal management of symptoms and, in many cases, significant residual impairment. Additionally, the psychosocial ramifications of narcolepsy are often neglected. Recently two new pharmacologic treatment options, solriamfetol and pitolisant, have been approved for adults, and the indication for sodium oxybate in narcolepsy has been expanded to include children. In recent years, there has been an uptick in patient-centered research, and promising new diagnostic and therapeutic options are in development. This paper summarizes current and prospective pharmacological therapies for treating both EDS and cataplexy, discusses concerns specific to children and reproductive-age women with narcolepsy, and reviews the negative impact of health-related stigma and efforts to address narcolepsy stigma.

show abstract

Section: Challenges and Prospects For Specific Populations With Narcomentioning

confidence: 99%